Diligence memo · auto-generated · as of July 2, 2026
Vignette Bio, Inc.
Vignette Bio, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Vignette Bio, Inc. operates in Biotech / Pharma, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vignette Bio, Inc. has raised $105M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $105M on 2024-07-17.
Most recent recorded round closed around 2024-07-17.
Valuation (modeled)modeled
Provath models Vignette Bio, Inc. at approximately $1.1B (range $488M–$1.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.58× the median modeled value of Series D+ Biotech / Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 23 mo ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 93% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Alto Pharmacy Holdings, Inc., Colossal Biosciences Inc., Vedanta Biosciences, Inc., Seismic Therapeutic, Inc., PharmaCann Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.